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Abstract
The introduction of next-generation sequencing (NGS) in the field of cancer research has boosted worldwide efforts
of genome-wide personalized oncology aiming at identifying predictive biomarkers and novel actionable targets.
Despite considerable progress in understanding the molecular biology of distinct cancer entities by the use of this
revolutionary technology and despite contemporaneous innovations in drug development, translation of NGS findings
into improved concepts for cancer treatment remains a challenge. The aim of this article is to describe shortly the NGS
platforms for DNA sequencing and in more detail key achievements and unresolved hurdles. A special focus will be
given on potential clinical applications of this innovative technique in the field of radiation oncology.
Introduction
Recent technological advances in DNA sequencing with
greater speed and resolution at lower costs has provided
new insights in cancer genetics. The next-generation se-
quencing (NGS) technology is tremendously facilitating
the in-depth genome-wide search for genetic alterations
which might significantly contribute to aggressive and/or
treatment-resistant phenotypes of cancers, thereby es-
tablishing the basis for the development of molecularly
targeted therapy. High-throughput sequencing of dis-
tinct cancer entities in large-scale projects has improved
our understanding of the disease-specific mutational pat-
terns [1–4] and the ‘Darwinian’ selection forces involved
in subclonal tumor evolution resulting in highly hetero-
geneous tumors. Initially, NGS has been developed for de-
tection of DNA-based alterations. However, it can also
assess other molecular aberrations, including those in the
epigenome [5, 6], transcriptome [7, 8] or RNAome [9]. In
this review we will only briefly discuss the technical
principle of NGS for DNA sequence analysis. For more de-
tailed information we would like to refer the reader to the
excellent reviews of Metzker et al. [10], Meyerson et al. [2]
and Wong et al. [11]. We will instead focus on key achieve-
ments in cancer genetics and potential clinical applications of
this innovative technique in the field of radiation oncology.
The advantages of NGS
Next-generation sequencing has rapidly been evolv-
ing within the last decade [10]. This high-throughput
method offers several advantages over classical capillary
electrophoresis-based ‘Sanger’ sequencing including in-
creased speed and resolution at dramatically lower costs
compared to the older sequencing technologies. To
illustrate the remarkable progress achieved by NGS,
the Human Genome Project which used first-generation
‘Sanger’ sequencing technology to sequence the human
genome took over 10 years and nearly 3 billion USD to
achieve its goal [12–14]. By next-generation sequencing
an individual human genome can now be sequenced in
less than 2 weeks for approximately 5000 USD [15].
In theory, the whole genome does not need to be se-
quenced to identify genetic alterations in most human
cancer-associated genes. More than 85 % of pathogenic
mutations are found within the protein-coding regions
of the genome [16], which collectively are referred to as
the “human exome”. This already dramatically reduces
the regions that need to be sequenced for personalized
oncology, thereby decreasing costs and time for whole
exome sequencing of one sample to approximately 1,500
USD and 48 h (the exact prices mainly depend on the
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NGS platform, the required sequencing depth and are
exclusive of the costs for bioinformatics). Furthermore
and probably even more relevant for integration into
clinical trials [17] or routine diagnostic applications [18],
focusing on a selected panel of genes with established
impact in cancer progression and/or a proven role in
treatment resistance is possible which offers the oppor-
tunity for detection of rare genetic variants at very high
sensitivity [2, 17] in all types of samples including archival
formalin-fixed, paraffin-embedded (FFPE) tissue [18, 19]
and plasma cell-free circulating tumor DNA [20].
The technical principle behind NGS
DNA sequencing was initially developed in 1975 by
Sanger and Coulson [21] and these techniques are still
used widely today. ‘Sanger’ sequencing is based on the
use of oligonucleotide primers specifically binding to
either side of the target DNA region which is then amp-
lified in a polymerase chain reaction (PCR). The use of
chain-terminating nucleotides in the DNA synthesis
process allows the generation of different copies of the
original DNA template at all possible lengths, which are
separated by capillary electrophoresis. By using specifically
labelled chain-terminating nucleotides (A, C, T or G) the
original DNA sequence can be assembled.
NGS is based on the principle of sequencing in a mas-
sively parallel fashion. This means that up to millions of
DNA fragments can be sequenced at the same time.
Initially, DNA is fragmented into short segments called
a shotgun library. Adaptors are ligated to the ends of
each fragment. These adaptors are themselves short
sequences of DNA which have primer binding sites for
subsequent amplification. The shotgun library can subse-
quently be enriched for the sequences of interest, using
different approaches [22, 23]. As one example, probes
which correspond to the target regions, e.g. the human
exome, and which are immobilized on beads or a solid
plate can be used in order to physically separate the target
DNA fragments from the remaining DNA. Alternatively,
custom arrays can be designed to enrich for specific
groups of genes of interest (cancer gene panels). Following
enrichment, the fragment library can be sequenced on
next-generation sequencing platforms from several manu-
facturers (for a comprehensive review of the differing plat-
form techniques see Metzker et al. [10]. Recording of the
captured sequences occurs at live mode in a massively par-
allel fashion when the fluorescent signals from dye-labelled
nucleotides in the nascent DNA strands on each bead,
channel or cluster are detected during DNA synthesis.
The challenge of big data analysis from NGS
Whilst large amounts of sequencing data can be generated
relatively quickly, data analysis can be time-consuming
and difficult. The first problem is the large size of NGS
raw data files, especially for results from WES or WGS.
For example, non-compressed FASTQ files from human
WGS with a mean coverage of 30x requires up to 200
gigabytes, making data transfer and storage of even small
WGS projects a real challenge. These estimates do not
include the disk space required for any downstream ana-
lysis. Development of streamlined, highly automated pipe-
lines for pre-processing of raw data, alignment or de novo
assembly of reads, quality control, copy number variation
(CNV) and/or SNP calling is essential and high-capacity
server solutions are mandatory. The key first step of data
processing is the alignment of the sequence reads to a
reference genome. Three characteristics of NGS data
complicate this task. First, read lengths are relatively short
(in average 26–330 bp) [10] compared to capillary-based
‘Sanger’ sequencing, which decreases the likelihood that a
read can be mapped to one unique location. Second, reads
from NGS platforms contain higher rates of sequencing
errors, especially in regions of homopolymer repeats [10].
Subsequent validation of novel variants by ‘Sanger’ sequen-
cing to exclude technical sequencing errors is therefore
highly recommended. This technical limitation of NGS is
also underlined by the results from a recent study which
revealed a higher rate of false-positive single nucleotide
variations detected by WES compared to WGS and a con-
siderable fraction of insertions and deletions detected by
both WES and WGS which could not be confirmed by
subsequent Sanger sequencing [24].
By all means, in each individual case most of the iden-
tified variants will represent single nucleotide polymor-
phisms (SNPs) of no pathogenic relevance [25]. These
can be removed either by filtering against sequencing re-
sults from ‘control’ DNA of the same patient’s normal
tissue or, if such control is not available, against data sets
from public databases such as the NCBI dbSNP and the
‘1000-genomes’ project [25]. The remaining variants can
be filtered against public collections of genetic alterations
in cancer, such as the Catalogue Of Somatic Mutations In
Cancer (COSMIC) database (http://cancer.sanger.ac.uk)
which as of August 2014 contained over 2 million coding
mutations, more than 70,000 gene fusions or genome re-
arrangements and almost 700,000 abnormal copy number
variants [26]. By such an approach, genetic variants with
known/potential oncogenic function can be identified.
An additional approach to separate biologically rele-
vant from irrelevant variants often utilizes new software
tools (SIFT [27, 28], PolyPhen-2 [29], mutation-assessor
[30]) which are now widely available and help to deter-
mine which mutations may have a functional impact on
the encoded protein, which are likely to be pathogenic,
or which are rather neutral variants without biological
effect. These methods are generally based on the as-
sumption that important amino acids will be conserved
in the protein family, and that changes at well-conserved
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positions are likely to be deleterious [27]. For example,
given a protein sequence SIFT chooses related proteins
and obtains an alignment of these proteins with the query.
Based on the amino acids appearing at each position in
the alignment, SIFT calculates the probability that an
amino acid at a position is tolerated or deleterious [27].
MutSig is another algorithm which has been developed
at the Broad Institute of Harvard and MIT in 2007 [31].
MutSig is currently broadly used to identify driver muta-
tions among large numbers of passenger mutations. In
contrast to the above mentioned methods, MutSig takes
into account that background mutation processes occurred
during formation of tumors and it considers the mutations
of each gene to identify genes that were mutated more
often than expected by chance [4]. Besides looking for
abundance above background, MutSig looks for positive se-
lection in genes, i.e. increased numbers of non-synonymous
vs. silent mutations or mutation clusters at hotspots. Its ad-
vanced version (MutSigv2.0) takes also into account the
functional impact of mutations (as estimated by the above
mentioned tools SIFT, PolypPhen-2, Mutation Assessor,
etc). In addition, incorporation of the covariates DNA repli-
cation time, chromatin state (open/closed), and general
level of transcription activity into the background model
has been shown to substantially reduce the number of
false-positive findings [4].
These in-silico methods certainly assist in the filtering
process, however their results still need to be cautiously
interpreted in conjunction with the involved gene and
certainly have their limitations. Methods like MutSig
identifying driver gene mutations based on background
mutation rates rely on a correct estimation of this back-
ground rate in a given tumor type and at a defined gen-
omic region in order to keep the number of false
positives to a minimum [4]. Other algorithms under-
estimate functional changes in poorly conserved posi-
tions [32]. As a result, frequency-based methods with
loose background mutation rates will detect driver can-
didates with a probably high rate of false positives. On
the other hand, methods implementing stricter models
will identify more specific candidate lists but might
miss some true cancer driver genes. Combination of
complementary methods might overcome these limita-
tions [3] and will certainly increase the knowledge gain
from NGS studies. Last but not least, functional studies
in preclinical models for elucidation of the mode of
interaction of genetic variants with biological processes
in tumor cells are indispensable for validation of NGS
findings and are certainly mandatory before NGS tech-
nologies should move into clinical applications [33].
Translation into clinical practice can certainly only be
achieved by multidisciplinary research approaches in
order to extract meaningful diagnostic interpretation
from large NGS datasets.
Novel approaches for personalization of
radiotherapy
Over the last two decades, technological advances in
treatment planning and delivery have improved the qual-
ity of radiotherapy in terms of precise dose application
to the target volume together with minimal dose to nor-
mal tissue. Despite these achievements, a fundamental
question that remains unresolved is whether based on the
molecular profile of their tumors it is possible to prospect-
ively identify patients who are more likely to benefit from
radiotherapy. Personalized radiotherapy could be achieved
by establishing biomarkers which can classify radiosensi-
tive/-resistant tumors and/or tumor-surrounding normal
tissue before initiation of treatment. To achieve such goal,
previous studies have mostly evaluated single biomarkers
or functional assays of DNA damage repair as predictor of
intrinsic cellular radiosensitivity. Among others, assess-
ment of the cell survival fraction [34] or the number of
residual DNA double strand breaks after ex vivo irradi-
ation of tumor cells [35] or normal tissue [36, 37] as well
as in vivo determination of the extent of tumor hypoxia
[38] have been evaluated extensively. Although promising
according to preliminary clinical data, none of them have
become routine yet which might be due to low robustness
of some of these in-vivo assays [36].
The generation of high-throughput data sets in the
omics era has provided a novel and complementary op-
portunity in biomarker discovery. Using high-throughput
transcriptome analysis, it has been previously shown that
prediction of cellular radiosensitivity of tumor cell lines by
expression analysis of a defined set of genes clearly outper-
formed assays of single gene analysis [39]. The value of
this molecular signature as predictive biomarker for radio-
sensitivity was already confirmed in a large clinical cohort
[40] speaking for its clinical potential. Another interesting
approach is the use of hypoxia gene expression signatures
for selecting patients who likely benefit from the inclusion
of hypoxia-modifying drugs in regimens of radio- [41] or
radiochemotherapy [42].
Beside the influence of gene expression levels, individ-
ual differences in cellular radiosensitivity are thought to
be at least partly determined by germ-line genetic vari-
ants. Rare variants which are likely to be functional can
only be detected by high-throughput DNA sequencing,
made now affordable by the NGS technology. Up to
date, only few studies used NGS for assessment of the
exact role of SNPs for treatment outcome after radio-
therapy. Recently, the role of germ-line SNPs and rare
variants in MRE11A as predictive biomarkers of both
tumor response and toxicity following definitive radio-
therapy of muscle-invasive bladder cancer was analyzed
by this technology [43]. Carriers of at least one of six
rare MRE11A variants had a significantly higher risk of
local failure in the radiotherapy arm, whereas no such
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association was seen in the surgically treated patient
cohort [43]. It will certainly be interesting to expand such
type of analysis to a broader spectrum of cancer types.
For elucidating the role of somatic mutations in radio-
resistance NGS has first been applied in bacteria [44]. In
a model of cellular adaption to irradiation, extremely
radioresistant E.coli strains were generated from the re-
spective founder cells by repetitive cycles of increasing
irradiation doses. Whole genome sequencing revealed a
large number of genomic alterations in the radioresistant
descendants of which only few were recurrent muta-
tions, suggesting that multiple mechanisms can contrib-
ute to radiation resistance and distinct evolutionary
pathways leading to this phenotype. Intriguingly, despite
this heterogeneity, clear genetic patterns also emerged.
Not unexpectedly, mutations clustered more frequently
in genes of DNA double strand break repair.
In two recent NGS studies in locally advanced squa-
mous cell carcinoma of the head and neck (HNSCC) our
group has evaluated the role of somatic mutations in a
set of cancer-related genes for the efficacy of definitive
[45] and adjuvant chemoradiation [46]. Our studies
could confirm previous reports of poor efficacy of radio-
therapy in HNSCC tumors harboring disruptive TP53
mutations [47, 48]. For the first time, we demonstrated a
possible role of mutations in NOTCH1 and key driver
genes (PIK3CA, KRAS, NRAS and HRAS) as predictive
biomarkers of outcome after chemoradiation. Moreover,
our studies also confirmed that archival formalin-fixed
paraffin-embedded (FFPE) specimens are indeed suitable
for targeted NGS although in series older than 8–10
years a considerable portion of samples (up to 30 %)
might fail due to the high extent of DNA fragmentation
(IT, ms in preparation, July 2015).
NGS is also increasingly being used for the dissection
of the mechanisms involved in treatment-induced clonal
selection in the course of acquired treatment resistance.
To our knowledge, only one study so far has addressed
this question in a model of radioresistance [49]. In this
study, DNA-targeted sequencing was performed on pre-
and post-treatment tumor tissues from rectal cancer
patients who failed to respond to neoadjuvant chemo-
radiation. Mutant variants previously associated with
radioresistance including TP53 were detected in post-
treatment residual tumor tissue from non-responders.
In line with an important role of TP53 mutation in
radioresistance, an increase in allele frequency of aber-
rant TP53 variants as well as an increase in mutant p53
expression levels was observed in all cases in which the
tumor harbored a hotspot missense mutation in the
DNA-binding domain of p53. These data strongly sug-
gest that chemoradiation exerts a selection pressure
that leads to the increase in the relative portion of tumor
cells expressing mutant p53 protein [49]. Strategies of
downregulating mutant p53 [50] or refolding it into its
wild-type confirmation [51] might prove effective in sensi-
tizing tumor cells to chemoradiation in this scenario.
Another interesting approach with potential impact in
radiooncology which makes use of NGS represents a
novel method named XR-seq. This technique can be ap-
plied for genome-wide mapping of DNA excision repair
[52]. The underlying principle is that human nucleotide
excision repair generates two incisions surrounding the
site of damage, creating fragments of approximately 30
nucleotides. In XR-seq, these fragments are enriched by
immunoprecipitation of specific repair proteins which are
tightly bound to the excised DNA fragments. By subject-
ing this fragment library to NGS maps of global and
transcription-coupled DNA repair can be generated. This
novel method will allow uncovering repair characteristics
and sequence preferences of treatment-induced DNA
damage and as such might facilitate studies of the effects
of mutational patterns on transcriptional activity on DNA
repair in human tumor cells. This method should also
prove useful in determining the effects of drugs like
histone-modifying therapeutics or poly ADP ribose poly-
merase (PARP) inhibitors on nucleotide excision repair,
and how they eventually interfere with radio- or chemo-
sensitivity of tumor cells.
The immunomodulatory effects of radiation have
been widely documented (for review see Burnette &
Weichselbaum [53]) and immunogenic cell death was
identified as key component not only of targeted ther-
apies but also conventional treatment modalities in-
cluding radiation [54]. It could thus be speculated that
radiation of tumors with large numbers of genetic alter-
ations, with a portion of them serving as putative neo-
antigens, is more likely to induce anti-tumor immunity
compared to radiation of tumors with low number of
alterations. In support of this assumption, the total
number of immunogenic mutations per se (identified
by WES) was positively correlated with overall survival
of cancer patients treated with standard regimens [55].
Combining radiation and immune checkpoint blockade
which already demonstrated synergistic anti-tumor re-
sponses in animal models [56] are promising strategies
which are based on the above-mentioned principles. In-
tegration of NGS-based mutational profiling in upcom-
ing clinical trials of such combinatory treatment are
anticipated and will determine the predictive value of
the mutational load and/or the number of immuno-
genic mutations in this setting.
Intertumoral and intratumoral genomic
heterogeneity: a real challenge for personalized
medicine
As stated above, the technological advances coming along
with NGS have permitted rapid analysis of individual
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cancer genomes at high resolution on single-nucleotide
level. By this technical advancement, an astonishing het-
erogeneity between individual tumors has been revealed,
with only a limited number of somatic alterations shared
between tumors of the same histopathologic subtype. This
large genetic heterogeneity can be illustrated in the model
of HNSCC. Cases in this disease entity with a history of
heavy smoking and alcohol consumption belong to the
group of highly genetically instable tumors [57], most
likely resulting from the extensive DNA damage that has
been caused by tobacco carcinogen exposure for years. As
of December 2014, preprocessed and preanalysed muta-
tional data from 3 independent whole exome NGS studies
in HNSCC [58–60] in total reporting on 412 HNSCC cases
were available at cbioportal (http://www.cbioportal.org).
We used these data which have been filtered using tissue-
matched control sequences to exclude germ-line variants
for a more detailed assessment of the extent of genetic het-
erogeneity in HNSCC. Overall, somatic non-synonymous
mutations were detected in 15,293 genes. However, only
357 (2.3 %) of these genes were altered by mutation in >3 %
of the tumors. In 127 (36 %) of the more frequently affected
genes the mutation occurred within hotspot regions but for
only 75 genes (15 %) the same base position was involved
in more than one tumors. This means that recurrent muta-
tions at hotspot regions were detected in only 0.5 % of all
genes altered by mutations (Fig. 1). Alternatively, when the
non-synonymous mutations were filtered using the
MutSigv2.0 algorithm according to the background
mutational rate per gene rather than their prevalence
in HNSCC, only 51 genes (0.3 % of all affected genes)
were identified as significantly mutated genes.
A second example for tumors of very high genetic het-
erogeneity is cutaneous melanoma [4]. In a landmark
WES study on paired tumor and normal genomic DNA
from 135 patients with melanoma an overall number of
86,813 coding mutations were detected at a 2:1 ratio of
non-synonymous to synonymous events, suggestive for a
high passenger mutation load [61]. Filtering against the
basal mutation rates using MutSig [31] produced a list
of 544 significantly mutated genes. By refining the algo-
rithm to select for non-synonymous mutations of pre-
dicted functional consequence the authors reduced the list
of candidate drivers to eleven genes harboring significant
functional mutation burden. Interestingly, these genes in-
cluded six well-known cancer genes (BRAF, NRAS, PTEN,
TP53, CDKN2A, MAP2K1) and five new candidates
(PPP6C, RAC1, SNX31, TACC1, and STK19) [61].
The huge genetic heterogeneity in these types of can-
cer underlines the need for advanced bioinformatics
models for data analysis. It also impressively illustrates
the need of identifying key oncogenic driver pathways
rather than individual genes as targets of precision medi-
cine. This assumption is also supported by the observa-
tion that many low-frequency mutations in breast and
colorectal tumors, each of them having small effects on
cell survival [62]. It is thus rather unlikely that genome
sequencing will uncover a single target as the “Achilles
heel” of a tumor.
Exacerbating the complexity of the genetic landscape
of tumors, intratumoral heterogeneity in terms of spatial
and temporal differences in the mutational patterns of
key driver genes has recently been demonstrated for
renal [63, 64], lung [65], colorectal [66, 67] and breast
cancer [68]. Beyond etiologic, microenvironmental and
tumor-specific factors which all might contribute to such
genetic heterogeneity, therapy may act as further ex-
ogenous source of genome instability. Consistent with
this, in a recent study using the genetic model system
Caenorhabditis elegans cisplatin treatment has been
found to lead to a striking increase in base substitutions
as well as an elevated rate of larger structural alterations
[69]. Importantly, among the mutations found to be in-








Muts in hotspot regions
(non-recurrent base position)
only 0.5% of all non-synonymous mutations
Muts in hotspot regions
(recurrent base position)
genes affected
by mutations in 
3% of cases
Fig. 1 Genetic heterogeneity of squamous cell carcinomas of the head and neck region (HNSCC). The relative distribution of genes affected by
mutations is shown according to their mean prevalence within the three analyzed study cohorts (≤3 % vs. >3 % of cases) and their frequency of
occurrence at hotspot regions and/or recurrent base positions. The results shown here are based upon somatic mutation data generated by the
TCGA Research Network [60], Stransky et al. [59] and Agrawal et al. [58]
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have been linked to tumor progression and drug resist-
ance like activating HRAS mutations at codons 12 and
13 [70, 71]. Temozolomide which is broadly used as
radiosensitizer in brain tumors and sarcomas has been
found to leave an imprint in the cancer genome in the
form of an elevated rate of C > T transitions [57]. Con-
cerning potential mutagenicity of radiotherapy, TP53
[72] as well as c-MYC among others were identified as
radiosensitive gene loci [73].
In the light of accumulating evidence for high inter-
and intratumoral genomic heterogeneity the identifica-
tion of the relevant driver mutation(s) among passengers
in an individual cancer biopsy at a defined stage of dis-
ease represents a significant hurdle in the development
of NGS-based molecular diagnostics and personalized
treatment. One approach to overcome such hurdle
might represent deep sequencing of cell-free circulating
tumor DNA derived from blood plasma for personalized
cancer genomic profiling [20, 74–78], assuming that
genetic variants which are present in tumors only at
subclonal level (and which are probably not captured by
the diagnostic biopsy) are finally and inevitably released
by dying tumor cells to this common reservoir.
Future perspectives
Exciting new data from a continuously growing number
of NGS cancer studies nourish the hope that this tech-
nology will also significantly contribute to increasing our
understanding of the molecular mechanisms of radiore-
sistance. However, many more studies will certainly be
needed to determine the functional consequences of in-
dividual mutations or distinct mutational patterns for
cellular radiosensitivity and the individual tumor’s re-
sponse to radiotherapy. Proteomics is expected to pro-
vide additional important information that will guide
candidate drug selection and recent advances in prote-
omic techniques [79, 80] have opened new avenues for
optimized cancer treatment. The application of these
techniques will not only allow the monitoring of protein-
protein interactions, posttranslational modification and
drug-target engagement directly in cells or tissues but will
also represent a valuable tool for identifying off-target
drug effects [80]. The latter feature will certainly also
foster attempts to develop less toxic protocols of radio-
therapy combined with molecularly targeted radiosensi-
tizing agents.
The future of personalized radiation therapy will most
likely not only include DNA-based NGS. It will also
apply other high-throughput technologies such as RNA
sequencing that in parallel provides quantitative gene ex-
pression as well as mutational status. Overall, it can be
reasoned that integration of mutational patterns from
NGS analysis and other omics data together with func-
tional measures of cellular radiosensitivity in systems
biology models will strongly improve the power of out-
come prediction and optimize current treatment selection
algorithms for individual patients.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
IT, FN, RK, SL, MM, performed the data analysis of public NGS data in HNSCC
described in the manuscript. IT, RK, AS, WW, UK and VB jointly developed the
structure and arguments for the paper. All authors performed a literature
research. IT wrote the manuscript. All authors discussed, made critical
revisions and approved the final manuscript.
Author details
1Department of Radiooncology and Radiotherapy, Charité University Hospital
Berlin, Translational Radiation Oncology Research Laboratory, Charitéplatz 1,
10117 Berlin, Germany. 2German Cancer Research Center (DKFZ) and German
Cancer Consortium (DKTK) partner site, Heidelberg, Germany. 3Group for
Computational Modelling in Medicine, Institute for Theoretical Biology,
Humboldt Universität, Berlin, Germany. 4Institute of Pathology, University
Hospital and National Center for Tumor Diseases, Heidelberg, Germany.
5Institute of Pathology, University Hospital and National Center for Tumor
Diseases, Heidelberg, Germany. 6Charité Comprehensive Cancer Center,
Charité University Hospital, Berlin, Germany.
Received: 22 May 2015 Accepted: 7 August 2015
References
1. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C.
Emerging landscape of oncogenic signatures across human cancers. Nat
Genet. 2013;45(10):1127–33.
2. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes
through second-generation sequencing. Nat Rev Genet. 2010;11(10):685–96.
3. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C,
Reimand J, et al. Comprehensive identification of mutational cancer driver
genes across 12 tumor types. Sci Rep. 2013;3:2650.
4. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et
al. Mutational heterogeneity in cancer and the search for new cancer-
associated genes. Nature. 2013;499(7457):214–8.
5. Ku CS, Naidoo N, Wu M, Soong R. Studying the epigenome using next
generation sequencing. J Med Genet. 2011;48(11):721–30.
6. Sarda S, Hannenhalli S. Next-generation sequencing and epigenomics
research: a hammer in search of nails. Genomics Inform. 2014;12(1):2–11.
7. Morozova O, Hirst M, Marra MA. Applications of new sequencing
technologies for transcriptome analysis. Annu Rev Genomics Hum Genet.
2009;10:135–51.
8. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for
transcriptomics. Nat Rev Genet. 2009;10(1):57–63.
9. Derks KW, Misovic B, van den Hout MC, Kockx CE, Gomez CP, Brouwer RW,
et al. Deciphering the RNA landscape by RNAome sequencing. RNA Biol.
2015;12(1):30–42.
10. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet.
2010;11(1):31–46.
11. Wong KM, Hudson TJ, McPherson JD. Unraveling the genetics of cancer:
genome sequencing and beyond. Annu Rev Genomics Hum Genet.
2011;12:407–30.
12. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial
sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.
13. McPherson JD, Marra M, Hillier L, Waterston RH, Chinwalla A, Wallis J, et al.
A physical map of the human genome. Nature. 2001;409(6822):934–41.
14. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et
al. A map of human genome sequence variation containing 1.42 million
single nucleotide polymorphisms. Nature. 2001;409(6822):928–33.
15. Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome
Sequencing Program (GSP) Available at: www.genome.gov/
sequencingcosts. Accessed [2015].
16. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al.
Targeted capture and massively parallel sequencing of 12 human exomes.
Nature. 2009;461(7261):272–6.
Tinhofer et al. Radiation Oncology  (2015) 10:183 Page 6 of 8
17. Simon R, Roychowdhury S. Implementing personalized cancer genomics in
clinical trials. Nat Rev Drug Discov. 2013;12(5):358–69.
18. Kriegsmann M, Endris V, Wolf T, Pfarr N, Stenzinger A, Loibl S, et al. Mutational
profiles in triple-negative breast cancer defined by ultradeep multigene
sequencing show high rates of PI3K pathway alterations and clinically relevant
entity subgroup specific differences. Oncotarget. 2014;5(20):9952–65.
19. Hedegaard J, Thorsen K, Lund MK, Hein AM, Hamilton-Dutoit SJ, Vang S, et
al. Next-generation sequencing of RNA and DNA isolated from paired fresh-
frozen and formalin-fixed paraffin-embedded samples of human cancer and
normal tissue. PLoS One. 2014;9(5):e98187.
20. Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, et al.
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for
tumor genotyping and personalized medicine in a prospective trial across
all tumor types. Mol Oncol. 2015;9(4):783–90.
21. Sanger F, Coulson AR. A rapid method for determining sequences in DNA
by primed synthesis with DNA polymerase. J Mol Biol. 1975;94(3):441–8.
22. Johansson H, Isaksson M, Sorqvist EF, Roos F, Stenberg J, Sjoblom T, et al.
Targeted resequencing of candidate genes using selector probes. Nucleic
Acids Res. 2011;39(2):e8.
23. Bodi K, Perera AG, Adams PS, Bintzler D, Dewar K, Grove DS, et al. Comparison
of commercially available target enrichment methods for next-generation
sequencing. J Biomol Tech. 2013;24(2):73–86.
24. Belkadi A, Bolze A, Itan Y, Cobat A, Vincent QB, Antipenko A, et al.
Whole-genome sequencing is more powerful than whole-exome sequencing
for detecting exome variants. Proc Natl Acad Sci U S A. 2015;112(17):5473–8.
25. Genomes Project C, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin
RM, et al. A map of human genome variation from population-scale
sequencing. Nature. 2010;467(7319):1061–73.
26. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al.
COSMIC: exploring the world’s knowledge of somatic mutations in human
cancer. Nucleic Acids Res. 2015;43(Database issue):D805–11.
27. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein
function. Nucleic Acids Res. 2003;31(13):3812–4.
28. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat
Protoc. 2009;4(7):1073–81.
29. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et
al. A method and server for predicting damaging missense mutations. Nat
Methods. 2010;7(4):248–9.
30. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein
mutations: application to cancer genomics. Nucleic Acids Res.
2011;39(17):e118.
31. Getz G, Hofling H, Mesirov JP, Golub TR, Meyerson M, Tibshirani R, et al.
Comment on “The consensus coding sequences of human breast and
colorectal cancers”. Science. 2007;317(5844):1500.
32. Reimand J, Wagih O, Bader GD. The mutational landscape of
phosphorylation signaling in cancer. Sci Rep. 2013;3:2651.
33. Schott AF, Perou CM, Hayes DF. Genome Medicine in Cancer: What’s in a
Name? Cancer Res. 2015;75(10):1930–5.
34. Pouliliou SE, Lialiaris TS, Dimitriou T, Giatromanolaki A, Papazoglou D,
Pappa A, et al. Survival Fraction at 2 Gy and gammaH2AX Expression
Kinetics in Peripheral Blood Lymphocytes From Cancer Patients:
Relationship With Acute Radiation-Induced Toxicities. Int J Radiat Oncol
Biol Phys. 2015;92(3):667–74.
35. Menegakis A, Eicheler W, Yaromina A, Thames HD, Krause M, Baumann M.
Residual DNA double strand breaks in perfused but not in unperfused areas
determine different radiosensitivity of tumours. Radiother Oncol.
2011;100(1):137–44.
36. van Waarde MA, van Assen AJ, Konings AW, Kampinga HH. Feasibility of
measuring radiation-induced DNA double strand breaks and their repair by
pulsed field gel electrophoresis in freshly isolated cells from the mouse
RIF-1 tumor. Int J Radiat Oncol Biol Phys. 1996;36(1):125–34.
37. Rube CE, Grudzenski S, Kuhne M, Dong X, Rief N, Lobrich M, et al. DNA
double-strand break repair of blood lymphocytes and normal tissues
analysed in a preclinical mouse model: implications for radiosensitivity
testing. Clin Cancer Res. 2008;14(20):6546–55.
38. Zips D, Eicheler W, Bruchner K, Jackisch T, Geyer P, Petersen C, et al. Impact
of the tumour bed effect on microenvironment, radiobiological hypoxia
and the outcome of fractionated radiotherapy of human FaDu squamous-
cell carcinoma growing in the nude mouse. Int J Radiat Biol.
2001;77(12):1185–93.
39. Eschrich S, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, et al. Systems
biology modeling of the radiation sensitivity network: a biomarker discovery
platform. Int J Radiat Oncol Biol Phys. 2009;75(2):497–505.
40. Eschrich SA, Fulp WJ, Pawitan Y, Foekens JA, Smid M, Martens JW, et al.
Validation of a radiosensitivity molecular signature in breast cancer. Clin
Cancer Res. 2012;18(18):5134–43.
41. Toustrup K, Sorensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J, et al. Gene
expression classifier predicts for hypoxic modification of radiotherapy with
nimorazole in squamous cell carcinomas of the head and neck. Radiother
Oncol. 2012;102(1):122–9.
42. Hassan Metwally MA, Ali R, Kuddu M, Shouman T, Strojan P, Iqbal K, et al.
IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer
nimorazole concomitant with accelerated radiotherapy in head and neck
squamous cell carcinoma. Radiother Oncol. 2015.
43. Teo MT, Dyrskjot L, Nsengimana J, Buchwald C, Snowden H, Morgan J, et al.
Next-generation sequencing identifies germline MRE11A variants as markers
of radiotherapy outcomes in muscle-invasive bladder cancer. Ann Oncol.
2014;25(4):877–83.
44. Harris DR, Pollock SV, Wood EA, Goiffon RJ, Klingele AJ, Cabot EL, et al. Directed
evolution of ionizing radiation resistance in Escherichia coli. J Bacteriol.
2009;191(16):5240–52.
45. Tinhofer I, Budach V, Endris V, Stenzinger A, Weichert W. Genomic profiling
using targeted ultra-deep next-generation sequencing for prediction of
treatment outcome after concurrent chemoradiation: Results from the
German ARO-0401 trial. J Clin Oncol. 2014;32(5s):abstr 6002.
46. Tinhofer I, Budach V, Linge A, Lohaus F, Gkika E, Stuschke M, et al.
Mutational patterns of HPV+ and HPV- squamous cell carcinomas of the
head and neck (SCCHN) and their interference with outcome after adjuvant
chemoradiation: A multicenter biomarker study of the German Cancer
Consortium Radiation Oncology Group. J Clin Oncol. 2015;33(5s):abstr 6006.
47. Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, Buijze M, Bloemena E,
Snijders PJ, et al. Prognostic significance of truncating TP53 mutations in head
and neck squamous cell carcinoma. Clin Cancer Res. 2011;17(11):3733–41.
48. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, et al. TP53
disruptive mutations lead to head and neck cancer treatment failure through
inhibition of radiation-induced senescence. Clin Cancer Res. 2012;18(1):290–300.
49. Sakai K, Kazama S, Nagai Y, Murono K, Tanaka T, Ishihara S, et al.
Chemoradiation provides a physiological selective pressure that increases
the expansion of aberrant TP53 tumor variants in residual rectal cancerous
regions. Oncotarget. 2014;5(20):9641–9.
50. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, et al.
Dietary downregulation of mutant p53 levels via glucose restriction:
mechanisms and implications for tumor therapy. Cell Cycle.
2012;11(23):4436–46.
51. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent
growth suppression distinguishes PRIMA-1 from known anticancer drugs: a
statistical analysis of information in the National Cancer Institute database.
Carcinogenesis. 2002;23(12):2011–8.
52. Hu J, Adar S, Selby CP, Lieb JD, Sancar A. Genome-wide analysis of human global
and transcription-coupled excision repair of UV damage at single-nucleotide
resolution. Genes Dev. 2015;29(9):948–60.
53. Burnette B, Weichselbaum RR. Radiation as an immune modulator. Semin
Radiat Oncol. 2013;23(4):273–80.
54. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in
cancer therapy. Annu Rev Immunol. 2013;31:51–72.
55. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al.
Neo-antigens predicted by tumor genome meta-analysis correlate with
increased patient survival. Genome Res. 2014;24(5):743–50.
56. Binder DC, Fu YX, Weichselbaum RR. Radiotherapy and immune checkpoint
blockade: potential interactions and future directions. Trends Mol Med. 2015
57. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et
al. Signatures of mutational processes in human cancer. Nature.
2013;500(7463):415–21.
58. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al.
Exome sequencing of head and neck squamous cell carcinoma reveals
inactivating mutations in NOTCH1. Science. 2011;333(6046):1154–7.
59. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al.
The mutational landscape of head and neck squamous cell carcinoma.
Science. 2011;333(6046):1157–60.
60. The Cancer Genome Atlas N. Comprehensive genomic characterization of
head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82.
Tinhofer et al. Radiation Oncology  (2015) 10:183 Page 7 of 8
61. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A
landscape of driver mutations in melanoma. Cell. 2012;150(2):251–63.
62. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The
genomic landscapes of human breast and colorectal cancers. Science.
2007;318(5853):1108–13.
63. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al.
Intratumor heterogeneity and branched evolution revealed by multiregion
sequencing. N Engl J Med. 2012;366(10):883–92.
64. Swanton C. Intratumor heterogeneity: evolution through space and time.
Cancer Res. 2012;72(19):4875–82.
65. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al.
Spatial and temporal diversity in genomic instability processes defines lung
cancer evolution. Science. 2014;346(6206):251–6.
66. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE.
Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in
primary colorectal adenocarcinomas and their corresponding metastases.
Clin Cancer Res. 2010;16(3):790–9.
67. Kreso A, O’Brien CA, van Galen P, Gan OI, Notta F, Brown AM, et al. Variable
clonal repopulation dynamics influence chemotherapy response in
colorectal cancer. Science. 2013;339(6119):543–8.
68. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour
evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–4.
69. Meier B, Cooke SL, Weiss J, Bailly AP, Alexandrov LB, Marshall J, et al. C.
elegans whole-genome sequencing reveals mutational signatures related to
carcinogens and DNA repair deficiency. Genome Res. 2014;24(10):1624–36.
70. Munoz EF, Diwan BA, Calvert RJ, Weghorst CM, Anderson J, Rice JM, et al.
Transplacental mutagenicity of cisplatin: H-ras codon 12 and 13 mutations
in skin tumors of SENCAR mice. Carcinogenesis. 1996;17(12):2741–5.
71. Cho HJ, Jeong HG, Lee JS, Woo ER, Hyun JW, Chung MH, et al. Oncogenic
H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/
Rac1 pathway in NIH3T3 cells. Evidence for association with reactive oxygen
species. J Biol Chem. 2002;277(22):19358–66.
72. Gonin-Laurent N, Gibaud A, Huygue M, Lefevre SH, Le Bras M, Chauveinc L,
et al. Specific TP53 mutation pattern in radiation-induced sarcomas.
Carcinogenesis. 2006;27(6):1266–72.
73. Wade MA, Sunter NJ, Fordham SE, Long A, Masic D, Russell LJ, et al. c-MYC
is a radiosensitive locus in human breast cells. Oncogene. 2014.
74. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al.
Noninvasive identification and monitoring of cancer mutations by targeted
deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68.
75. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of
circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med.
2013;368(13):1199–209.
76. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al.
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 2014;6(224):224ra24.
77. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An
ultrasensitive method for quantitating circulating tumor DNA with broad
patient coverage. Nat Med. 2014;20(5):548–54.
78. Frenel JS, Carreira S, Goodall J, Roda Perez D, Perez Lopez R, Tunariu N, et
al. Serial Next Generation Sequencing of Circulating Cell Free DNA
Evaluating Tumour Clone Response To Molecularly Targeted Drug
Administration. Clin Cancer Res. 2015.
79. Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et
al. Monitoring drug target engagement in cells and tissues using the
cellular thermal shift assay. Science. 2013;341(6141):84–7.
80. Savitski MM, Reinhard FB, Franken H, Werner T, Savitski MF, Eberhard D, et
al. Tracking cancer drugs in living cells by thermal profiling of the
proteome. Science. 2014;346(6205):1255784. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tinhofer et al. Radiation Oncology  (2015) 10:183 Page 8 of 8
